Primary Outcome
The median (IQR) number of organ support–free days was 12 (−1 to 17) in the P2Y12 inhibitor group and 11 (−1 to 18) in the usual care group. The median adjusted OR (AOR) for the effect of P2Y12 inhibitor on organ support–free days was 1.07 (95% CrI, 0.85-1.33; posterior probability of superiority, 72.9%) (